treatment and formulation aspects of NB32, in the United States
and certain foreign countries under the Patent Cooperation Treaty, or PCT. Use of a proprietary tri-layer NB32 tablet for weight loss is protected in the United States
by U.S. patent numbers 8,088,786 and 8,318,788, which are expected to expire in February 2029 and November 2027, respectively. In addition, the dose escalation schedule of Contrave is protected by U.S. patent 8,722,085, which is expected to expire in November 2027. Orexigen has filed other patent applications in the United States
and other parts of the world with the potential, if the patents issue, to extend intellectual property protection as late as 2034.
About Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is NB32. Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen's strategy for NB32 is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company has submitted applications for marketing authorization in the United States and Europe, with potential approvals in 2014. If approved, North American partner Takeda Pharmaceuticals will commercialize NB32 in the United States. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.
Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential,"
Page: 1 2 3 4 Related biology technology :1
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2014 PR Newswire.
All rights reserved
. Orexigen Therapeutics to Present at Upcoming Conferences2
. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors3
. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies4
. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 20135
. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference6
. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.7
. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee8
. Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes9
. The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist10
. Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference11
. Orexigen Receives CHMP Day 180 List of Outstanding Issues